LONDON, Dec.

- Journal of Clinical Lipidology publishes largest study comparing cancer risk of ezetimibe and ezetimibe/simvastatin to statin therapies using FDA database - BOSTON, March 25 /PRNewswire-USNewswire/ -- A new study shows no increased cancer risk with ezetimibe mono and ezetimibe/simvastatin combination treatments, compared to cancer rates of other powerful lipid-lowering statin therapies.

Being obese limits your life expectancy, and in some instances may be as hazardous as smoking.

By Associated Press MUNICH, Germany -- Results so far from three studies of the cholesterol-lowering drug Vytorin are not enough to prove or rule out a possible link to a higher risk of cancer, so the drug should be used with caution until more is known, editors of a leading medical journal urged Tuesday.

By Steve Sternberg The editors of a leading medical journal cautioned Tuesday that, without more data, it's impossible to rule out a link between the cholesterol-lowering drug Vytorin and cancer.